New Delhi, February 24: Alembic Pharmaceuticals on Tuesday announced that it has received final approval from the US Food and Drug Administration to market its generic version of Efinaconazole Topical Solution 10 percent in the United States.
The approval marks a significant regulatory milestone for the company as it strengthens its presence in the US generics market.
USFDA Grants Final Approval for ANDA
Alembic Pharmaceuticals confirmed that the US health regulator has granted final approval to its abbreviated new drug application for Efinaconazole Topical Solution 10 percent.The approved product is therapeutically equivalent to Jublia Topical Solution 10 percent marketed by Bausch Health Americas Inc. The approval enables Alembic to manufacture and distribute the antifungal medication in the US market.
The company stated that it was among the first abbreviated new drug application applicants to submit a substantially complete filing with a Paragraph IV certification, highlighting its early positioning in the product’s regulatory pathway.
Indication and Therapeutic Use
Efinaconazole Topical Solution 10 percent is indicated for the topical treatment of onychomycosis of the toenails. The infection is caused by Trichophyton rubrum and Trichophyton mentagrophytes, both of which are common fungal pathogens affecting toenails.With this approval, Alembic Pharmaceuticals expands its dermatology portfolio and strengthens its offering in antifungal therapies within the US market.
Market Opportunity in the US
According to IQVIA data, Efinaconazole Topical Solution recorded an estimated market size of USD 500 million for the 12 months ending December 2025. The sizeable market presents a commercial opportunity for Alembic as it prepares to enter the segment with its generic alternative.The approval aligns with the company’s strategy to enhance its product pipeline in regulated markets and leverage opportunities in high-value therapeutic categories.
Alembic Pharmaceuticals Share Price Movement
Shares of Alembic Pharmaceuticals closed 2.69 percent lower at Rs 750.15 per share on the BSE on Tuesday.The development comes amid continued regulatory progress by Indian pharmaceutical companies in the United States, which remains a key export destination for generic drug manufacturers.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.